Unchanged asymmetric dimethylarginine levels in non-diabetic, premenopausal obese women who have common risk factors for cardiovascular disease

Abstract

This study was performed to test whether plasma asymmetric dimethylarginine (ADMA) concentrations are related to obesity and obesity complications including decrement in insulin sensitivity and adiponectin levels, dyslipidemia and low-grade inflammation. Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) concentrations were analyzed by HPLC in 17 overweight (BMI > or = 25 kg/m2) and 40 obese (BMI > or = 30 kg/m2) premenopausal women. Age-matched healthy women were studied as controls. Obesity did not give rise to a significant change in circulating ADMA levels but reduced in SDMA levels. As compared with control subjects (0.441 +/- 0.102 microM), ADMA values in overweight and obese subjects were found to be as 0.412 +/- 0.102 and 0.436 +/- 0.093, respectively. No Pearson's association of ADMA with relevant risk variables for cardiovascular disease, including blood pressure, insulin sensitivity, inflammatory markers, lipid and adiponectin levels. However, in linear regression analysis, BMI, diastolic blood pressure, glucose, insulin, and IL-8 emerged as significant predictors of ADMA. In spite of obese women have elevated hs-CRP, triglyceride levels and decreased insulin sensitivity, adiponectin and HDL-cholesterol levels, all of which is closely linked risk factors for cardiovascular disease, circulating ADMA levels remained unchanged in obese individuals as compared with controls.

Asymmetric Dimethylarginine: Relationship with Circulating Biomarkers of Inflammation and Cardiovascular Disease Risk in Uncomplicated Obese Women

“…In our study we did not find any relationship betweenADMA and any of the anthropometric and biochemical parameters evaluated. Previous studies which investigated the relationship of ADMA with obesity, observed, in particular, a correlation of ADMA with BMI, glucose and insulin levels (16,(21)(22). Although our study did not confirm the existing evidence, the lack of correlations may be explained considering the limited sample size and the characteristics of our population.…”

“…Previous studies (16)(17) which evaluated the role of ADMA in the link between obesity and CD have been generally carried out on groups of obese subjects already affected by other complications. In this study we aim to quantify ADMA level in obese uncomplicated women (with no clinical, cardiac or metabolic complications) and in normal-weight controls and to investigate the relationship ofADMA with some anthropometric measurements, abdominal visceral (VAT) and subcutaneous (SAT) adipose tissue accumulation, biochemical, pro-inflammatory and pro-atherosclerotic factors of the subjects.…”

Asymmetric Dimethylarginine (ADMA) is Tightly Correlated with Growth in Juveniles without Correlations to Obesity Related Disorders

“…Furthermore, correlations of ADMA with obesity related symptoms of the metabolic syndrome are also discussed. Whereas some studies failed to show any correlation, others found a correlation between increased ADMA and obesity [14,23,24] . A possible explanation for an association of ADMA with metabolic disorders may be found in the hypercholsterolemic status of obese patients.…”

Serum asymmetric dimethylarginine and nitric oxide levels in obese postmenopausal women

“…Asymmetric dimethylarginine (ADMA), a major endogenous NOS inhibitor, may alter NO bioavailability under physiological and pathological conditions (11,12). Reports related to plasma ADMA concentrations in obese individuals are contradicting (13)(14)(15). Insulin resistance was shown to associate with elevated plasma ADMA levels (16), and this elevation was accompanied with obesity (17).…”